Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Lauren L Lohmer"'
Autor:
Lauren L Lohmer, Matthew R Clay, Kaleb M Naegeli, Qiuyi Chi, Joshua W Ziel, Elliott J Hagedorn, Jieun E Park, Ranjay Jayadev, David R Sherwood
Publikováno v:
PLoS Genetics, Vol 12, Iss 1, p e1005786 (2016)
Invadopodia are specialized membrane protrusions composed of F-actin, actin regulators, signaling proteins, and a dynamically trafficked invadopodial membrane that drive cell invasion through basement membrane (BM) barriers in development and cancer.
Externí odkaz:
https://doaj.org/article/f44cb6e4aa5b4ce4bcd0920fecf8f975
Autor:
Jie Zhou, Laura Curd, Lauren L. Lohmer, Joachim Ossig, Frank Schippers, Thomas Stoehr, Virginia Schmith
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 1, Pp 326-334 (2021)
Remimazolam is an ultra‐short acting benzodiazepine under development for procedural sedation and general anesthesia. Population pharmacokinetic analysis (PopPK) was conducted for remimazolam with arterial and venous samples previously, but results
Externí odkaz:
https://doaj.org/article/d4c0e8a70c674f4d93ac11f56122c405
Autor:
Abraham Q. Kohrman, Adam J. Schindler, Michalis Barkoulas, David R. Sherwood, David Q. Matus, Wan Zhang, Lauren L. Lohmer, Qiuyi Chi, Laura C. Kelley
Publikováno v:
Developmental Cell. 35:162-174
SummaryDespite critical roles in development and cancer, the mechanisms that specify invasive cellular behavior are poorly understood. Through a screen of transcription factors in Caenorhabditis elegans, we identified G1 cell-cycle arrest as a precis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fcff70ec1f1359e990bff5384631506
https://doi.org/10.1016/j.devcel.2015.10.002
https://doi.org/10.1016/j.devcel.2015.10.002
Publikováno v:
Cell Adhesion & Migration. 8:246-255
Over 20 years ago, protrusive, F-actin-based membrane structures, termed invadopodia, were identified in highly metastatic cancer cell lines. Invadopodia penetrate artificial or explanted extracellular matrices in 2D culture conditions and have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::624e726290c9f26d722a6fc036486c00
https://doi.org/10.4161/cam.28406
https://doi.org/10.4161/cam.28406
Publikováno v:
The Journal of Cell Biology
The basement membrane is a dense, highly cross-linked, sheet-like extracellular matrix that underlies all epithelia and endothelia in multicellular animals. During development, leukocyte trafficking, and metastatic disease, cells cross the basement m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b87b88ed566743c8e7c3e6fb9ab56bfc
https://doi.org/10.1083/jcb.201311112
https://doi.org/10.1083/jcb.201311112
Repurposing an endogenous degradation system for rapid and targeted depletion of C. elegans proteins
The capability to conditionally inactivate gene function is essential for understanding the molecular basis of development. In gene and mRNA targeting approaches, protein products can perdure, complicating genetic analysis. Current methods for select
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f159d5b1f0f50eafd101b66b7980d3df
https://europepmc.org/articles/PMC4302935/
https://europepmc.org/articles/PMC4302935/
Autor:
Jieun Park, Ranjay Jayadev, Joshua W. Ziel, Lauren L. Lohmer, Qiuyi Chi, Elliott J. Hagedorn, Matthew R. Clay, Kaleb M. Naegeli, David R. Sherwood
Publikováno v:
PLoS Genetics, Vol 12, Iss 1, p e1005786 (2016)
PLoS Genetics
PLoS Genetics
Invadopodia are specialized membrane protrusions composed of F-actin, actin regulators, signaling proteins, and a dynamically trafficked invadopodial membrane that drive cell invasion through basement membrane (BM) barriers in development and cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6274f1a8d21b91c5af3fa316927a03a4
https://doi.org/10.1371/journal.pgen.1005786
https://doi.org/10.1371/journal.pgen.1005786
Autor:
Schueller O; Kadmon, A Sanofi Company, Cambridge, MA, USA., Regev G; Kadmon, A Sanofi Company, Cambridge, MA, USA., Singh N; Quotient Sciences, Nottingham, UK., Willson A; Quotient Sciences, Nottingham, UK., Beville M; Quotient Sciences, Nottingham, UK., Kanji N; Quotient Sciences, Nottingham, UK., Lohmer L; Nuventra, Inc., Durham, NC, USA., Patel J; Kadmon, A Sanofi Company, Cambridge, MA, USA.
Publikováno v:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2024 May; Vol. 13 (5), pp. 491-498. Date of Electronic Publication: 2024 Feb 12.
Autor:
Schueller O; Kadmon Corporation, Inc., Cambridge, Massachusetts, USA., Lohmer L; Nuventra, LLC, Durham, North Carolina, USA., Xue H; Clario, Rochester, New York, USA., Darpo B; Clario, Rochester, New York, USA., Patel J; Kadmon Corporation, Inc., Cambridge, Massachusetts, USA.
Publikováno v:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Oct; Vol. 11 (10), pp. 1221-1232. Date of Electronic Publication: 2022 Jul 26.
Autor:
Schueller O; Kadmon Corporation, LLC, Cambridge, Massachusetts, USA., Willson A; Quotient Sciences, Nottingham, UK., Singh N; Quotient Sciences, Nottingham, UK., Lohmer L; Nuventra, LLC, Durham, North Carolina, USA., Alabanza A; Nuventra, LLC, Durham, North Carolina, USA., Patel J; Kadmon Corporation, LLC, Cambridge, Massachusetts, USA.
Publikováno v:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Jul; Vol. 11 (7), pp. 795-806. Date of Electronic Publication: 2022 Mar 01.